Список литературы

1. Савченко В.Г., ред. Программное лечение заболеваний системы крови. М.: Практика; 2012: 155 - 245.

2. Савченко В.Г., Паровичникова Е.Н. Острый промиелоцитарный лейкоз. Москва, Литерра, 2010, стр. 1 - 200.

3. National Comprehensive Cancer Network (NCCN) GUIDELINES FOR AML TREATMENT Version 2.2016. AML 1 - 6, MS 13 - 26. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf

4. Sanz MA¹, (http://www.ncbi.nlm.nih.gov/pubmed?term=SanzMA[Author]&cauthor=true&cauthor_uid=18812465) Grimwade D, (http://www.ncbi.nlm.nih.gov/pubmed?term=GrimwadeD[Author]&cauthor=true&cauthor_uid=18812465) Tallman MS, (http://www.ncbi.nlm.nih.gov/pubmed?term=TallmanMS[Author]&cauthor=true&cauthor_uid=18812465) Lowenberg B, (http://www.ncbi.nlm.nih.gov/pubmed?term=LowenbergB[Author]&cauthor=true&cauthor_uid=18812465) Fenaux P, (http://www.ncbi.nlm.nih.gov/pubmed?term=FenauxP[Author]&cauthor=true&cauthor_uid=18812465) Estey EH, (http://www.ncbi.nlm.nih.gov/pubmed?term=EsteyEH[Author]&cauthor=true&cauthor_uid=18812465) Naoe T, (http://www.ncbi.nlm.nih.gov/pubmed?term=NaoeT[Author]&cauthor=true&cauthor_uid=18812465) Lengfelder E, (http://www.ncbi.nlm.nih.gov/pubmed?term=LengfelderE[Author]&cauthor=true&cauthor_uid=18812465) , (http://www.ncbi.nlm.nih.gov/pubmed?term=[Author]&cauthor=true&cauthor_uid=18812465) , (http://www.ncbi.nlm.nih.gov/pubmed?term=[Author]&cauthor=true&cauthor_uid=18812465) Burnett AK, (http://www.ncbi.nlm.nih.gov/pubmed?term=BurnettAK[Author]&cauthor=true&cauthor_uid=18812465) Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009 Feb 26;113(9): 1875 - 91 (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-Coco[Author]&cauthor=true&cauthor_uid=18812465)

5. Троицкая В.В., Паровичникова Е.Н, Соколов А.Н., Кохно А.В., Махиня С.А., Галстян Г.М., Константинова Т.С., Мазурок Л.А., Горячок И.Г., Коробкин А.В., Любченко М.А., Латышкевич О.А., Зверева А.В., Курцер М.А., Савченко В.Г. Лечение острого промиелоцитарного лейкоза на фоне беременности. Тер. архив 2013 N 10, стр 56 - 63 (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

6. Martin S. Tallman and Jessica K. Altman How I treat acute promyelocytic leukemia Blood 2009, 114: 5126 - 5135 (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

7. Platzbecker U, Avvisati G, Lo-Coco F et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2016 Jul 11. pii: JC0671982. [Epub ahead of print]. pp 1 - 8. (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

8. Lo-Coco F, Cicconi L, Breccia M. Current standard treatment of adult acute promyelocytic leukaemia. Br J Haematol. 2016 Mar; 172(6): 841 - 54. (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

9. Finsinger P, Breccia M, Minotti C et al. Acute promyelocytic leukemia in patients aged > 70 years: the cure beyond the age. Ann Hematol. 2015 Feb;94(2): 195 - 200 (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

10. Breccia M, Cicconi L, Lo-Coco F. ATRA ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia? Curr Opin Hematol. 2014 Mar; 21(2): 95 - 101 (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

11. Mantha S, Goldman DA, Devlin SM et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017 Jan 12. [Epub ahead of print] pp 1 - 22. (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

12. Mantha S, Tallman MS, Soff GA. What"s new in the pathogenesis of the_coagulopathy_in acute promyelocytic leukemia? Curr Opin Hematol. 2016 Mar; 23(2): 121 - 6 (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

13. Kwaan HC, Cull EH. The_coagulopathy_in acute promyelocytic leukaemia--what have we learned in the past twenty years. Best Pract Res Clin Haematol. 2014 Mar; 27(1): 11 - 8 (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

14. Leblebjian H, DeAngelo DJ, Skirvin JA et al. Predictive factors for all-trans retinoic acid-related_differentiation_syndrome_in patients with acute promyelocytic leukemia.Leuk Res. 2013 Jul; 37(7): 747 - 51. (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

15. Rogers JE, Yang D. Differentiation_syndrome_in patients with acute promyelocytic leukemia. J Oncol Pharm Pract. 2012 Mar; 18(1): 109 - 14 (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)

16. Vikram Mathews, Anu Korula, Uday Kulkarni et al. (http://www.ncbi.nlm.nih.gov/pubmed?term=Lo-CocoF[Author]&cauthor=true&cauthor_uid=18812465)Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition. Blood 2016 128:446; (http://www.bloodjournal.org/content/128/22/446)